Ex vivo treatment of patient biopsies as a novel method to assess colorectal tumour response to the MEK1/2 inhibitor, Selumetinib

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Novo, Sonia M ^a   Wedge, Stephen R ^b   Stark, Lesley A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; RAS PROTEIN; SELUMETINIB;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; BIOPSY; CELL PROLIFERATION; COLON; COLORECTAL TUMOR; DRUG EFFECT; FEMALE; GENETICS; HCT 116 CELL LINE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; RECTUM; TUMOR CELL LINE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BENZIMIDAZOLES; BIOPSY; CELL LINE, TUMOR; CELL PROLIFERATION; COLON; COLORECTAL NEOPLASMS; FEMALE; HCT116 CELLS; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MIDDLE AGED; MUTATION; RAS PROTEINS; RECTUM;

EID: 85029652828     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-12222-9     Document Type: Article

References (36)

1. Allemani, C. et al. Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2),. Lancet 385(9972), 977 (2015).
2. Weng, W. et al. Molecular therapy of colorectal cancer: progress and future directions,. Int. J. Cancer 136(3), 493 (2015).
3. McIntyre, R. E. et al. Mouse models of colorectal cancer as preclinical models,. Bioessays 37(8), 909 (2015).
4. Ellis, L. M. & Fidler, I. J. Finding the tumor copycat. Therapy fails, patients don't. Nat. Med. 16(9), 974 (2010).
5. Jackstadt, R. & Sansom, O. J. Mouse models of intestinal cancer,. J. Pathol. 238(2), 141 (2016).
6. Golovko, D. et al. Colorectal cancer models for novel drug discovery. Expert. Opin. Drug Discov. 10(11), 1217 (2015).
7. Ohta, Y. & Sato, T. Intestinal tumor in a dish,. Front Med. (Lausanne) 1, 14 (2014).
8. van de Wetering, M. et al. Prospective derivation of a living organoid biobank of colorectal cancer patients,. Cell 161(4), 933 (2015).
9. Puig, I. et al. A personalized preclinical model to evaluate the metastatic potential of patient-derived colon cancer initiating cells,. Clin. Cancer Res. 19(24), 6787 (2013).
10. Seol, H. S. et al. Development and characterization of a colon PDX model that reproduces drug responsiveness and the mutation profiles of its original tumor,. Cancer Lett. 345(1), 56 (2014).
11. Dame, M. K. et al. Human colon tissue in organ culture: preservation of normal and neoplastic characteristics,. In Vitro Cell Dev. Biol. Anim 46(2), 114 (2010).
12. Majumder, B. et al. Predicting clinical response to anticancer drugs using an ex vivo platform that captures tumour heterogeneity. 6, 6169 (2015).
13. Vescio, R. A. et al. In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture,. Proc. Natl. Acad. Sci. USA 84(14), 5029 (1987).
14. Vaira, V. et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors,. Proc. Natl. Acad. Sci. USA 107(18), 8352 (2010).
15. Rubio-Viqueira, B. et al. Optimizing the development of targeted agents in pancreatic cancer: Tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays,. Mol. Cancer Ther. 6(2), 515 (2007).
16. H. Davies, et al. Mutations of the BRAF gene in human cancer, 417(6892), 949 (2002).
17. Yang, S. H., Sharrocks, A. D. & Whitmarsh, A. J. MAP kinase signalling cascades and transcriptional regulation,. Gene 513(1), 1 (2013).
18. Zenonos, K. & Kyprianou, K. RAS signaling pathways, mutations and their role in colorectal cancer,. World J. Gastrointest. Oncol. 5(5), 97 (2013).
19. Halilovic, E. et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling,. Cancer Res. 70(17), 6804 (2010).
20. Davies, B. R. et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-Activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models,. Mol. Cancer Ther. 6(8), 2209 (2007).
21. Wang, J. Y. et al. Recent advances of MEK inhibitors and their clinical progress,. Curr. Top. Med. Chem. 7(14), 1364 (2007).
22. Yeh, T. C. et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-Activated protein kinase kinase 1/2 inhibitor,. Clin. Cancer Res. 13(5), 1576 (2007).
23. Adjei, A. A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-Activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers,. J. Clin. Oncol. 26(13), 2139 (2008).
24. Banerji, U. et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): A phase I open-label multicenter trial in patients with advanced cancer,. Clin. Cancer Res. 16(5), 1613 (2010).
25. Bennouna, J. et al. A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens,. Invest New Drugs 29(5), 1021 (2011).
26. Leijen, S. et al. A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors,. Cancer Chemother. Pharmacol. 68(6), 1619 (2011).
27. Tolcher, A. W. et al. Antitumor Activity in RAS-Driven Tumors by Blocking AKT and MEK,. Clin. Cancer Res. 21(4), 739 (2015).
28. Dry, J. R. et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244),. Cancer Res. 70(6), 2264 (2010).
29. Migliardi, G. et al. Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas,. Clin. Cancer Res. 18(9), 2515 (2012).
30. Din, F. V., Dunlop, M. G. & Stark, L. A. Evidence for colorectal cancer cell specificity of aspirin effects on NF kappa B signalling and apoptosis,. Br. J. Cancer 91(2), 381 (2004).
31. Stark, L. A. & Dunlop, M. G. Nucleolar sequestration of RelA (p65) regulates NF-kappaB-driven transcription and apoptosis,. Mol. Cell Biol. 25(14), 5985 (2005).
32. Balmanno, K. et al. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines,. Int. J. Cancer 125(10), 2332 (2009).
33. Lee, H. J. et al. Drug resistance via feedback activation of Stat3 in oncogene-Addicted cancer cells,. Cancer Cell 26(2), 207 (2014).
34. Tentler, J. J. et al. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer,. Mol. Cancer Ther. 9(12), 3351 (2010).
35. Thoms, H. C. et al. Nucleolar targeting of RelA(p65) is regulated by COMMD1-dependent ubiquitination,. Cancer Res. 70(1), 139 (2010).
36. O'Hara, A. et al. p300-mediated acetylation of COMMD1 regulates its stability, and the ubiquitylation and nucleolar translocation of the RelA NF-kappaB subunit,. J. Cell Sci. 127(Pt 17), 3659 (2014).